On June 10, WuXi Biologics fell 4.21% in regular trading, trading at 29.4 HKD/share, with trading volume of 131 million HKD. The decline extends multi-day selling pressure following a series of US regulatory actions targeting the WuXi group of companies.

On the news front, the US Commerce Department's Bureau of Industry and Security recently added WuXi Biologics and WuXi Biologics (Shanghai) to its Unverified List (UVL), citing inability to verify end-use of exported items. Additionally, on June 8 (US time), the US Department of Defense listed WuXi AppTec — a closely associated company — on its 1260H Chinese Military Companies list. These developments have compounded concerns over geopolitical risk exposure across the CXO sector, with WuXi Biologics deriving approximately 50% of revenue from the US market. The company stated it has been importing bioreactor hardware controllers subject to US export controls with prior BIS approval over the past decade, and that UVL designation is distinct from the more restrictive Entity List. WuXi Biologics has been actively conducting share buybacks, repurchasing 653.7 million HKD worth of shares on June 8 alone, as it seeks to stabilize market confidence amid ongoing headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)